Theralase Technologies shares positive interim results from Phase II Bladder Cancer study

About this update from Theralase Technologies Inc.

[{"type":"text","content":"Theralase Technologies shares positive interim results from Phase II Bladder Cancer study\n \n \n (NewsDirect)\n \n \n \n \n Theralase Technologies CEO Roger\nDuMoulin-White joined Steve Darling from Proactive to share interim\ndata from a Phase II clinical study designed to treat patients\ndiagnosed with Bacillus Calmette-Guérin Unresponsive, Non-Muscle\nInvasive Bladder Cancer and Carcinoma In-Situ with a patented\ninvestigational study drug Ruvidar, subsequently activated by a\nproprietary investigational study laser system equipped with\nfiber-optic light emitters and detectors.\n \n \n DuMoulin-White discussed more about the study and what the\ninterim data is telling them about the study.\n \n \n He also talked\nabout the company and the other vertical it has with its Cool Laser\nTherapy which is focused on the research, development, production and\ndistribution of medical laser technologies for healing pain.\n \n \n \n Contact Details\n \n \n \n Proactive Investors\n \n \n +1\n604-688-8158\n \n \n \n [email protected]\n \n \n \n Copyright (c) 2023 TheNewswire - All rights reserved.\n \n \n","length":1490,"tagName":"div"}]

More updates from Theralase Technologies Inc.